EUVIMEDEUVIMED entdecken
Crossref

Discovery of Pan-KRAS Inhibitor GNE-6226: Harnessing an Aminopyridine Pharmacophore to Broadly Target KRAS Mutants

Benjamin D. Ravetz, Mark Merchant, BinQing Wei, Elizabeth H. Kelley, Maureen H. Beresini, Kamakoti P. Bhat, Jingwei Cai, Xiaodan Chang, Stefan Chun, Stephanie Dale, Cecile C. de la Cruz, Darlene Dela Cruz und 25 weitere

Journal of Medicinal Chemistry · 21.11.2026

DOI: 10.1021/acs.jmedchem.6c02035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.11.2026. Verfasst von Benjamin D. Ravetz und 36 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Biological and Environmental Research, National Institute of General Medical Sciences.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RAS is the most frequently mutated oncogene in human cancer, yet limited treatments are available for patients with mutations beyond KRAS G12C. While pan-RAS inhibitors have entered the clinic to benefit a broader population of patients harboring RAS mutations, we sought to develop pan-KRAS inhibitors (selective for KRAS over HRAS and NRAS) that may offer an improved therapeutic index. Herein, we describe the discovery of GNE-6226, a pan-KRAS inhibitor exhibiting exquisite potency across a range of KRAS mutants. Using a structure-based design, we transitioned from mutant-selective inhibitors to a pan-KRAS inhibition profile, identifying the aminopyridine headgroup as a crucial motif. This headgroup establishes key ligand−protein interactions with conserved residues within the switch-II pocket while avoiding steric clashes with KRAS mutants. We present extensive cellular and in vivo profiling of GNE-6226, highlighting its robust MAPK pathway modulation and tumor growth inhibition in vivo across G12V- and G12D-mutant xenograft mouse models.

Förderung

  • Biological and Environmental Research
  • National Institute of General Medical Sciences

Zitieren

APA

Ravetz, B. D., Merchant, M., Wei, B., Kelley, E. H., Beresini, M. H., Bhat, K. P., Cai, J., Chang, X., Chun, S., Dale, S., Cruz, C. C. D. L., Cruz, D. D., Demircioglu, F. E., Deng, L., Gazzard, L., Gerosa, L., Hunsaker, T. L., Landry, M. L., Lee, K., …, & Terrett, J. A. (2026). Discovery of Pan-KRAS Inhibitor GNE-6226: Harnessing an Aminopyridine Pharmacophore to Broadly Target KRAS Mutants. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02035

Vancouver

Ravetz BD, Merchant M, Wei B, Kelley EH, Beresini MH, Bhat KP, et al. Discovery of Pan-KRAS Inhibitor GNE-6226: Harnessing an Aminopyridine Pharmacophore to Broadly Target KRAS Mutants. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02035

BibTeX
@article{Ravetz2026,
  author = {Ravetz, Benjamin D. and Merchant, Mark and Wei, BinQing and Kelley, Elizabeth H. and Beresini, Maureen H. and Bhat, Kamakoti P. and Cai, Jingwei and Chang, Xiaodan and Chun, Stefan and Dale, Stephanie and Cruz, Cecile C. de la and Cruz, Darlene Dela and Demircioglu, F. Esra and Deng, Lin and Gazzard, Lewis and Gerosa, Luca and Hunsaker, Thomas L. and Landry, Matthew L. and Lee, Kaylee and Lin, Eva and Lu, Aijun and Ma, Fang and Malhotra, Sushant and Murray, Jeremy M. and Rouge, Lionel and Saabye, Matthew J. and Larrocha, Pablo Saenz-Lopez and Segal, Ehud and Shao, Cheng and Sun, Yinlei and Wang, Weiru and Wu, Guosheng and Ye, Xin and Zhang, Yulai and Zou, Jun and Evangelista, Marie and Terrett, Jack A.},
  title = {Discovery of Pan-KRAS Inhibitor GNE-6226: Harnessing an Aminopyridine Pharmacophore to Broadly Target KRAS Mutants},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02035}
}
Kostenlos starten →